[Electroacupuncture of specific acupoints of Shaoyang Meridian relieves progression of chronic migrain by down-regulating expression of P2Y12 receptor in rats].

Researchers investigated how electroacupuncture might prevent chronic migraines from worsening by studying its effects on pain sensitivity and brain chemistry in rats. The study used 48 rats divided into six groups, with one group receiving electroacupuncture at three specific points along the Shaoyang meridian: Fengchi (GB20), Yanglingquan (GB34), and Waiguan (TE5). These points were stimulated with electrical current for 30 minutes before and during the creation of a chronic migraine condition. The results showed that electroacupuncture significantly reduced pain sensitivity in both the eye area and paws of the rats compared to untreated migraine rats. The treatment worked by lowering levels of specific proteins and receptors in the brain's pain processing center, particularly the P2Y12 receptor, which plays a role in central sensitization—the process that makes the nervous system overly responsive to pain. The electroacupuncture treatment performed better than medication in reducing some migraine markers. When researchers gave rats a drug that activated the P2Y12 receptor while receiving acupuncture, it partially blocked acupuncture's beneficial effects, suggesting this receptor is a key target. This study provides scientific evidence that electroacupuncture at specific Shaoyang meridian points may help prevent the progression from occasional to chronic migraines by calming overactive pain pathways in the nervous system. If you're considering acupuncture for migraine prevention, seek a licensed acupuncturist trained in traditional meridian point selection.

This study examined electroacupuncture effects on chronic migraine progression in 48 SD rats using a nitroglycerin-induced CM model. Treatment consisted of bilateral GB20, GB34, and TE5 stimulation (10/50 Hz, 30 min, 6 sessions). Compared to the model group, EA significantly increased periorbital and plantar mechanical pain thresholds (P<0.001) and decreased P2Y12 receptor expression, Iba-1, CGRP, and c-fos proteins in the trigeminal spinal caudal nucleus. Immunofluorescence and RT-qPCR confirmed reduced P2Y12-positive cells and mRNA expression. Co-administration of P2Y12 agonist (ADP) partially reversed EA benefits, while antagonist (MRS2395) replicated EA effects. EA outperformed topiramate in reducing P2Y12 expression markers (P<0.05-0.01). The mechanism appears to involve P2Y12 receptor downregulation with subsequent inhibition of microglial activation and central sensitization pathways. Clinical implications suggest Shaoyang meridian point selection may effectively prevent migraine chronification through modulation of purinergic signaling and neuroinflammatory cascades in trigeminal nociceptive pathways.